STOCK TITAN

Artelo Biosciences Inc Stock Price, News & Analysis

ARTL Nasdaq

Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.

Artelo Biosciences Inc (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company pioneering therapies targeting lipid-signaling pathways, including innovative approaches to cancer support care and neuropathic pain management. This page provides investors and researchers with verified updates on the company’s progress in developing novel treatments for conditions with high unmet medical needs.

Access comprehensive coverage of clinical trial milestones, regulatory developments, and strategic partnerships. Our curated news collection includes press releases about Artelo’s proprietary cocrystal technology, FABP5 inhibitor program, and advancements in cannabinoid-based therapeutics – all essential for tracking the company’s pipeline evolution.

Stay informed about critical updates including Phase trial results, intellectual property filings, and collaborations with global research institutions. Bookmark this page for real-time insights into how Artelo Biosciences is advancing treatments for chemotherapy-induced neuropathy, cancer-related anorexia, and inflammatory conditions through cutting-edge science.

Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) has announced positive results from its preliminary food effect evaluation of ART26.12, their novel non-opioid pain treatment candidate. The assessment was conducted as part of their successful Phase 1 single ascending dose (SAD) clinical trial.

The study demonstrated favorable safety outcomes with no serious adverse events reported. Key findings showed consistent exposure levels under fasted conditions with low inter-subject variability, indicating ART26.12 can be effectively administered with or without food. The drug showed predictable pharmacokinetics and a benign safety profile, crucial characteristics for a chronic pain treatment.

The company is now preparing to advance to a multiple ascending dose (MAD) study, scheduled to begin in Q4 2025, to further evaluate safety, tolerability, and pharmacokinetics with repeated dosing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
-
Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) reported Q2 2025 financial results and provided updates on its clinical pipeline. The company highlighted successful completion of Phase 1 Single Ascending Dose study for ART26.12 with positive safety results and is preparing for Multiple Ascending Dose study in Q4 2025.

Key financial metrics include Q2 net loss of $3.2 million ($5.61 per share), R&D expenses of $1.9 million, and cash position of $2.1 million. The company secured additional funding through convertible notes ($0.9M) and two PIPE transactions totaling $10.9 million.

Artelo expects multiple clinical data readouts in Q3 2025, including Phase 2 results from the CAReS study of ART27.13 for cancer anorexia-cachexia syndrome. The company also presented promising preclinical data for ART12.11 in depression treatment and plans first-in-human studies in early 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
-
Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) has received a Notice of Allowance from the European Patent Office for patent application No. 21827629.3, covering the intended commercial formulation of ART27.13, their peripherally selective cannabinoid agonist. The patent protection extends through December 2041 and covers compositions of ART27.13 dispersed in polyethylene glycol.

The drug is currently in Phase 2 clinical trials (CAReS study) for cancer-related anorexia, which affects over 60% of advanced-stage cancer patients. In Phase 1, ART27.13 demonstrated positive results, with more than 60% of participants showing stabilized or reversed weight loss. Initial Phase 2 results are expected in Q3 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.12%
Tags
none
Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) has secured a $9.475 million private placement to implement a groundbreaking Solana (SOL) treasury strategy, becoming the first publicly-traded pharmaceutical company to adopt SOL as a core reserve asset. The financing includes the sale of 906,687 shares at $10.45 per share, along with two sets of three-year warrants.

The placement brings total proceeds since June 2025 to $10.9 million. Lead investor Bartosz Lipiński, former Head of Engineering at Solana Labs and Metaplex inventor, will serve as a technical partner through his company CUBE. The Board has approved expanding the SOL treasury strategy over time while maintaining adequate working capital for therapeutic development.

The private placement is expected to close around August 5, 2025, with R.F. Lafferty & Co. serving as advisor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
crypto private placement
-
Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) has received positive guidance from the UK's MHRA regarding its Phase 1 trial plans for ART12.11, a novel cocrystal combining CBD and Tetramethylpyrazine (TMP) for treating anxiety and depression. The MHRA endorsed a streamlined development approach and suggested ART12.11 may qualify for the Innovative Licensing and Access Pathway (ILAP), potentially accelerating development and market access.

Preclinical studies demonstrated ART12.11's efficacy comparable to sertraline (Zoloft) with superior cognitive restoration. The cocrystal showed effectiveness in stress-induced anxiety and depression models where CBD alone was ineffective. The company's patents for ART12.11 extend through 2038 in 20 countries, with clinical trials expected to begin in early 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14%
Tags
-
Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) presented positive preclinical data for its lead FABP5 inhibitor ART26.12 at the 35th Annual International Cannabinoid Research Society Symposium. The study demonstrated that ART26.12, a first-in-class, non-opioid, non-steroidal analgesic drug candidate, effectively reduced osteoarthritis pain in preclinical models.

Key findings showed that ART26.12's efficacy matched naproxen, a common NSAID, while maintaining effectiveness throughout a four-week chronic dosing period without developing tolerance. The drug increased plasma levels of endocannabinoids 2-AG and OEA, correlating with improved weight-bearing ability in affected limbs. Importantly, ART26.12 may offer safety advantages over NSAIDs, which typically cause gastrointestinal side effects in one-third of patients and increase gastric ulcer risks five-fold.

[ "Drug candidate ART26.12 showed efficacy comparable to naproxen in treating osteoarthritis pain", "No tolerance development observed during four-week chronic dosing period", "Potential safety advantages over NSAIDs, which typically cause side effects in 33% of patients", "Demonstrated direct effect on relevant endocannabinoid plasma levels" ]
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.85%
Tags
none
Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) has announced promising preclinical results for its drug candidate ART12.11, a CBD:TMP cocrystal, in treating stress-induced depression. The data, presented at the 35th Annual International Cannabinoid Research Society Symposium, demonstrates the drug's effectiveness comparable to sertraline (Zoloft) in treating depression-related behaviors.

Key findings show that ART12.11's 28-day treatment significantly improved depression-related behaviors in male rats, including restoration of hedonic and social behaviors. Notably, ART12.11 showed superior cognitive benefits compared to sertraline, successfully reversing stress-induced deficits in spatial and short-term memory without negative impacts on social memory.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.49%
Tags
none
-
Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) has announced positive results from its first-in-human Phase 1 Single Ascending Dose (SAD) study of ART26.12, a novel non-opioid pain treatment candidate. The study, involving 49 subjects, demonstrated favorable safety and pharmacokinetic profiles for the first orally active Fatty Acid Binding Protein 5 (FABP5) inhibitor tested in humans.

Key findings from the study include excellent safety results with only mild, transient, and self-resolving adverse events, predictable pharmacokinetics with dose-dependent linear absorption, and a wide safety margin between therapeutic plasma concentrations and highest exposure levels. The drug represents a first-in-class approach targeting the multibillion-dollar pain management market.

The chronic pain therapeutics market exceeded $97 billion globally in 2023 and is projected to surpass $159 billion by 2030. A Multiple Ascending Dose study is planned to commence in Q4 2025 to further evaluate ART26.12's safety, tolerability, and pharmacokinetics with repeated dosing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
95.43%
Tags
none
-
Rhea-AI Summary

Artelo Biosciences (Nasdaq: ARTL) has secured a $1.425 million At-the-Market private placement financing through a definitive securities purchase agreement. The company will issue 136,844 shares of common stock and 93,179 pre-funded warrants, along with warrants to purchase additional shares at $5.82 and $10.00 per share.

The funding will support the announcement of clinical data from two phase 1 studies for ART26.12 and a phase 2 study readout from the CAReS trial for ART27.13. Notably, $250,000 of the net proceeds will be allocated to purchase SOL digital currency, with the remaining funds used for general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.07%
Tags
private placement
Rhea-AI Summary
Artelo Biosciences (NASDAQ: ARTL) has announced a 6-for-1 reverse stock split effective June 13, 2025, approved by its Board of Directors on May 20, 2025. The clinical-stage pharmaceutical company, which focuses on lipid-signaling pathway modulation for cancer, pain, and neurological treatments, implemented this split to meet Nasdaq's minimum $1.00 per share closing bid price requirement for continued listing. Following the reverse split, every six shares will automatically convert into one share, reducing outstanding shares to approximately 546,667. The company's warrants and derivatives will automatically adjust to reflect the split, while shareholders' pro-rata ownership percentages remain unchanged. Trading under the new CUSIP number 04301G607 will commence at market open on June 13.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags

FAQ

What is the current stock price of Artelo Biosciences (ARTL)?

The current stock price of Artelo Biosciences (ARTL) is $9 as of August 27, 2025.

What is the market cap of Artelo Biosciences (ARTL)?

The market cap of Artelo Biosciences (ARTL) is approximately 12.5M.
Artelo Biosciences Inc

Nasdaq:ARTL

ARTL Rankings

ARTL Stock Data

12.50M
699.97k
0.34%
1.6%
2.57%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOLANA BEACH